Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) and MacroGenics (NASDAQ:MGNX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.
Valuation & Earnings
This table compares Intellia Therapeutics and MacroGenics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Intellia Therapeutics | $67.67 million | 21.24 | -$412.69 million | ($3.35) | -3.06 |
| MacroGenics | $149.50 million | 0.92 | -$74.62 million | ($0.22) | -9.84 |
MacroGenics has higher revenue and earnings than Intellia Therapeutics. MacroGenics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Intellia Therapeutics and MacroGenics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intellia Therapeutics | 4 | 7 | 9 | 1 | 2.33 |
| MacroGenics | 1 | 1 | 3 | 0 | 2.40 |
Intellia Therapeutics currently has a consensus target price of $21.44, indicating a potential upside of 109.44%. MacroGenics has a consensus target price of $8.50, indicating a potential upside of 292.61%. Given MacroGenics’ stronger consensus rating and higher possible upside, analysts plainly believe MacroGenics is more favorable than Intellia Therapeutics.
Profitability
This table compares Intellia Therapeutics and MacroGenics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intellia Therapeutics | -805.75% | -64.74% | -50.72% |
| MacroGenics | -8.70% | -109.26% | -18.70% |
Risk and Volatility
Intellia Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.
Summary
MacroGenics beats Intellia Therapeutics on 9 of the 15 factors compared between the two stocks.
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.
About MacroGenics
MacroGenics, Inc. is a biotechnology company focused on discovering and developing antibody-based medicines, primarily for cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company works on its own drug candidates and collaborates with other pharmaceutical and biotechnology companies. Its research uses antibody-engineering technologies, including platforms designed to engage immune cells against tumors and to deliver therapeutic payloads to cancer cells. MacroGenics’ portfolio has included margetuximab, marketed as Margenza, an antibody treatment approved in the United States for certain patients with HER2-positive metastatic breast cancer.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
